While a lower relapse rate did not reach statistical significance in all studies [ 158 , 159 ], a recent meta-analysis shows that rituximab administered during an acute iTTP episode not only lowers the relapse rate vs. control, but also reduces mortality [ 160 ].
← all excerpts
Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management.
1
—
—